The global anti-snoring devices and snoring surgery market procedures is largely consolidated. In 2014, GE Healthcare, Philips Healthcare, and Medtronic Plc. were the leading players in the market. They had collectively held a share of 93.69% in terms of value. Each of the key players possess exceptionally strong distribution chains and a wide product array under their belts.
According to a new research report released by Transparency Market Research, the threat exuded by new entrants to the global anti-snoring devices and snoring surgery market is expected to remain moderate in the years to come. Key players hold a monopoly over the market through high rates of mergers and acquisitions, while new players are also deterred by high development costs and high costs of surgery.
The global market for anti-snoring devices is expected to be evaluated at US$22.70 bn by 2024. It is projected at a CAGR of 3.9% from 2016 to 2024 and is expected to reach US$16.70 bn by the end of 2016. The global market for snoring surgery procedures is expected to expand at a CAGR of 3.3% from 2016 to 2024. This market’s revenue is expected to reach US$370.95 mn by the end of 2016 and US$481.35 mn by the end of 2024.
This 172 page report gives readers a comprehensive overview of the anti-snoring devices and snoring surgery market. Browse through 73 data tables and 5 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/antisnoring-devices-and-snoring-surgery-market.html
Continuous positive airway pressure devices are expected to continue being the leading anti-snoring device in terms of revenue for the near future. By 2024, this device segment is expected to generate a revenue of US$16.47 bn. Meanwhile, owing to high demand, tongue stabilizing devices are expected to show the leading CAGR of 5.14% from 2016 to 2024.
North America to Continue Leading Anti-snoring Devices and Snoring Surgery Procedures Consumption
North America has consistently generate the leading demand volume for anti-snoring devices and snoring surgery procedures. By the end of 2024, North America is expected to generate US$11.15 bn in revenue from this market. This region has consistently received a timely upgrade of technologies in this field, coupled with a high demand from a large volume of people who are aware of the options.
On the other hand, Asia Pacific is taking the lead in terms of growth in demand by expanding at a projected CAGR 5.2% in revenue from 2016 to 2024. The growth rate is attributed to the significant rate of increase in awareness along with the rising disposable incomes of people.
Growing Sleep Deprivation and Sleep Apnea Cases Propel use of Anti-snoring Devices and Surgery
“Sleep deprivation is a huge problem the people of today’s world are facing. A large number of people are suffering from it and are consequently susceptible to falling prey to chronic diseases, including obesity, hypertension, depression, and diabetes. This forms the core of all reasons driving the need for anti-snoring devices and snoring surgery procedures,” states a TMR analyst.
Sleep apnea is affecting a regularly increasing number of people around the world. Studies conducted by organizations such as the ESADA have already pointed to the incremental growth rate of sleep apnea cases. These patients are high-priority recipients of anti-snoring devices and snoring surgery procedures.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving anti-snoring devices and snoring surgery market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6910
Patient Compliance Still Low in Snoring Diagnostics, Hampers Anti-Snoring Device Sales
As stated in earlier research studies, close to a staggering 80% of the patients that were recommended for the usage of CPAP devices were non-compliant to the treatment, citing complaints made of the treatments being too uncomfortable or the devices being too difficult to handle. Most of the patients have shown compliance in the early stages of treatment, but the number of compliant patients dwindles over time due to these issues along with common side-effects such as throat dryness, nasal congestion, or nasal passage dryness.
“Research and development efforts do need to be stepped up, as they already have been by several key players. Examples in recent innovations in this market include the Provent’s release of light, small and battery-operated CPAP devices that can be controlled using Bluetooth communication,” adds the analyst.
The information presented in this review is based on a Transparency Market Research report, titled, “Anti-snoring Devices and Snoring Surgery Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Due to the highly fragmented nature of the global regulatory affairs outsourcing market, only a handful of large players have been able to gain significant share in this market over the past couple of years, says a new report by Transparency Market Research (TMR). This, however, has intensified the competitive rivalry in the market with players contending to deliver top-notch services. The top seven players in the market including Quintiles Transnational Holdings Inc., ICON plc, Pharmaceutical Product Development LLC, and PAREXEL International Corporation collectively held a share of 55% in the global market in 2014. The presence of a large number of small and medium-sized companies in the market has been advantageous to the bargaining power of clients.
The scenario demands regulatory affairs outsourcing service providers to top in terms of timeliness and quality. With increasing acceptance of electronics submissions from health governing bodies and compliance agencies, technological advancements will favor regulatory affairs outsourcing service providers to gain competitive edge, says the TMR report.
This 76 page report gives readers a comprehensive overview of the regulatory affairs outsourcing market. Browse through 10 data tables and 18 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/global-regulatory-affairs-outsourcing-market.html
The global market for regulatory affairs outsourcing was worth US$1.9 bn in 2014 and is projected to rise at a CAGR of 11.5% between 2015 and 2023. As such, the market will reach a valuation of US$5.7 bn by 2023.
Cost-effective Outsource Activities Befit over In-house Regulatory Maintenance
With the medical industry witnessing an increased rate of product innovations from companies vying to make a mark in the highly competitive market, investments on research and development are on the rise. In this regard, cost pressures and intense competition are pushing companies to discover new ways to contain costs incurred at the time of regulatory operations and practices principal to the life sciences industry. Outsourcing is increasingly being preferred over in-house data management as it is considered to be cost-effective and resource-efficient way of managing vast amounts of data generated during clinical trials, approvals, and patent approvals.
Moreover, strict regulatory framework in place that governs every facet of development and marketing of medical drugs and device mandate that regulatory documents to be in sync with pre-defined writing guidelines. This is further boosting the need for professional service providers that specialize in data handling related to regulatory affairs thereby further augmenting the need of dependable service providers for regulatory affairs outsourcing.
Varied Regulations Encourages Global Companies to Seek On-the-ground Expertise Help
With life sciences companies continually striving to spread their wings across the globe, the challenges of keeping up with varied and constantly changing regional, local, and national regulations can be overwhelming without expert help. In this scenario, outsourcing regulatory affairs to service providers that have a successful global footprint will be most suitable.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving regulatory affairs outsourcing market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3528
On a regional consideration, regulatory affairs service providers in the emerging economies of Asia Pacific and Latin America are expected to account for the leading number of outsourcing projects worldwide. An increasing number of biopharmaceutical companies are taking off from emerging economies to venture into large markets of North America and Europe.
Product improvement and setting up research and commercialization units is the focus of emerging economies due to cheap resources and cheap cost of raw materials. The large population of Asia Pacific makes for a lucrative regional market for the medical industry. These factors are benefitting the regulatory affairs outsourcing markets in these regions and will help them gain a strong foothold in the next few years.
The review presented is based on the findings of Transparency Market Research report, titled “Regulatory Affairs Outsourcing Market (Services – Regulatory Submissions, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
In 2014, the three leading players in the global nanotechnology drug delivery market – Amgen, Inc., Teva Pharmaceuticals, and Novartis – had held a collective share of 26.3%. This extremely fragmented market comprises of a large number of players that are already globally prominent while still having close to half its size dedicated to regional and local players.
As per the findings revealed by Transparency Market Research in its report, the degree of competition in the global nanotechnology drug delivery market is extremely high, owing to the large number of existing players in it. The demand for nanotechnology drug delivery systems is exceptionally high and is increasing at a fast pace. Additionally, the scope of invention and innovation is still very high, allowing players to find success in even niche roles.
This 120 page report gives readers a comprehensive overview of the nanotechnology drug delivery market. Browse through 12 data tables and 45 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nanotechnology-drug-delivery.html
The global market for nanotechnology drug delivery is expected to continue its bold CAGR of 12.5% within a forecast period from 2015 to 2023, in terms of revenue. This revenue is expected to reach US$51,969.7 mn by the end of 2016 and US$118,527.2 mn by the end of 2023. In terms of technologies, the global nanotechnology drug delivery market has been dominated by the segment of nanoparticles. By the end of 2023, the applications of nanoparticles in drug delivery are expected to generate US$33,543.2 mn in revenue.
North America Retains Dominant Usage and Scope of Drug Delivery Methods
North America has consistently held the leading spot in the global nanotechnology drug delivery market in terms of value. By the end of 2023, North America is expected to hold 44,450.5 mn of the revenue generated in the global nanotechnology drug delivery market. The primary reason for this is the medical and healthcare advancements that this region had already possessed over others. Close to 80% of all research and development efforts in the global biopharmaceutical industry take place within the U.S., which is also the leading regional user of nanotechnology in healthcare and specifically, drug delivery.
On the other hand, the emerging Asia Pacific region and its booming healthcare sector has put forth its stronger foot. Key countries in this region are exhibiting a phenomenal rate of growth in the healthcare and medical devices industries. This rapid economic growth rate, coupled with a growing expenditure on healthcare by patients, and the steadily increasing demand for the treatment of chronic diseases, is what may set Asia Pacific on track to challenge the greater shares held by North America and Europe.
Nanotechnology Drug Delivery Finds Application Scope Against Multiple Diseases
“The global nanotechnology drug delivery market has one highly sought-after concept working in its favor: the efficacy with which drug delivery can be achieve using these techniques has allowed for the development of incredibly potent drugs that can be used to combat a lot of the top priority diseases of today. The list includes a number of infectious diseases, genetic disorders, pulmonary diseases, cardiovascular diseases, and several forms of cancer,” states a TMR analyst.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving nanotechnology drug delivery market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1822
The introduction of nanotechnology drug delivery has revolutionized the pharmaceutical industry on a much larger scale. The traditional pharmaceutical design of LADME has now been transformed to include other processes such as circulation time, targeting, and triggered activation.
Venture Funds Scarcity Slows Nanotechnology Drug Delivery Market Down
There are quite a few factors responsible for restraining the growth rate of the global nanotechnology drug delivery market. One of the key restraints is the relative lack of venture funds. There are significant investments being made into the market for research and development efforts. However, in the broader picture, the market is still in a very early and formative stage and is in need of deeper investment pools to progress at a satisfactory rate. Other problems include the long waiting time of approval processes and the general lack of accuracy regarding what fields are a part of nano-medicine.
The information presented in this review is based on a Transparency Market Research report, titled, “Nanotechnology Drug Delivery Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”
The global multiplexed diagnostics market is highly competitive and dominated by the three players accounting for a combined share of 59.5% in 2015. These top companies are: Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies. Transparency Market Research finds that the leading players are constantly offering a diverse product portfolio, investing in acquiring advanced technologies, and expanding their regional presence to gain a competitive edge over others.
The market is otherwise fragmented with the presence of numerous small and mid-sized enterprises holding minor shares. Acquiring high-performing patented technologies, strengthening of distribution network, and intensifying manufacturing activities require substantial investment. This results in a high degree of competition, which poses significant entry barriers for new players. In order to consolidate their presence across regions, the large players are actively resorting to partnerships, mergers, and acquisitions.
This 194 page report gives readers a comprehensive overview of the multiplexed diagnostics market. Browse through 24 data tables and 75 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html
According to TMR’s estimation, the valuation of the global market for multiplexed diagnostics exceeded US$6.0 bn at the end of 2016. From 2016 to 2024, the market is anticipated to exhibit a consistent growth to attain US$26.36 bn by 2024; the global market, when measured in terms of revenue, is expected to expand at a 20.3% CAGR over the forecast period.
Innovative Multiplex Diagnostic Platform to Transform Cardiovascular Care
Geographically, the global multiplexed diagnostics market is segmented into Asia Pacific, North America, Latin America, the Middle East & Africa, and Europe. North America occupied a major market share in 2015. The regional market is anticipated to lead the market along the forecast period. The impressive growth is attributed to a wide prevalence of cardiovascular diseases, rising incidence of cancer in the U.S., and increasing geriatric population. The rapidly evolving healthcare services and innovations in healthcare IT in the U.S. have created ample opportunities for several players, which is expected to propel the regional market. Coupled with this, an enlarged scope of various reimbursements from both public as well as private players is expected to trigger the market growth.
On the basis of application, the multiplexed diagnostics market is segmented into cardiac diseases, oncology, autoimmune diseases, allergies, and infectious disease diagnostic. Of these, cardiac diseases, oncology, and infectious disease diagnostics are prominent market segments providing lucrative opportunities for numerous players to capitalize on. The cardiac disease diagnostics market is anticipated to grow at the highest rate due to wide prevalence of cardiovascular diseases, coupled with the design of high-throughput multiplex diagnostic equipment.
Automation in Multiplex PCR Systems Opens Promising Avenues for Disease Diagnosis
The global multiplexed diagnostics market is primarily driven by the soaring R&D investments by public as well as private players in the areas of genomics and personalized therapies. Constant advances in multiplex diagnostic technology have led to the application of targeted assay for detecting various pathogens for a wide spectrum of chronic and life-threatening diseases, such as neurological and cardiovascular disorders. Multiplexed real-time polymerase chain reaction (PCR) assays, as precision-based diagnostics, enable the concurrent detection of specific pathogens in a single experiment. Automation in multiplex PCR assay has resulted in reduced hands-on-time and elimination of error with high sensitivity and specificity. Along with this, the application of real-time automated multiplex PCR kits helps in rapid detection and significant cost-savings for laboratories, boosting its demand across a large number of diagnostic facilities.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving multiplexed diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719
However, the high cost of multiplexed diagnostics assay equipment, combined with lack of operational expertise, is likely to impede the growth of the global multiplexed diagnostics market. Nevertheless, continuous automation in assay technology and application of high-throughput multiplexed PCRs for the detection of a wide range of pathogens are expected to open up exciting opportunities for the leading players.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Multiplexed Diagnostics Market (Technology – Very High Density, High Density, Medium Density, Low Density, and Next Generation Sequencing Assays; Application – Infectious Disease Diagnostics, Oncology, Autoimmune Diseases, Cardiac Diseases, Allergies, and Pregnancy & Fertility Testing; End Use – Academic Research Institutes, Hospitals, Pharmaceuticals Companies, Clinical Research Organizations, and Diagnostic Laboratories) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
The leading companies operating in the active pharmaceutical ingredients (API) market are Zhejiang NHU Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang Medicine Co., Ltd., Northeast Pharmaceutical Group Co., Ltd., and North China Pharmaceutical Group Corp. and they accounted for the major combined share in 2015. Transparency Market Research (TMR) observes that the top players are opting for strategic mergers and acquisitions to consolidate their shares. The presence of significant barriers to exit and high fixed costs incurred by companies have intensified the competitive landscape in the market.
In order to cut down manufacturing costs, a growing number of pharmaceutical companies, especially in Europe and North America, prefer to outsource manufacturing overseas. These companies which previously had manufacturing units in their home countries are increasingly shifting to regions with cheap availability of labor and raw materials. However, these APIs are subject to stringent regulations of the countries where the pharmaceutical companies are housed. In addition, several players are focusing on research and development activities to develop innovative formulations, notes TMR. The opportunity in the global active pharmaceutical ingredient market stood at US$134.70 bn in 2015. Rising at a CAGR of 6.3% from 2015 to 2023, the market is expected to reach a valuation of US$219.60 bn by the end of 2023.
This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html
Asia Pacific Offers Lucrative Growth Avenues to API Manufacturers
Geographically, North America is the leading market as it accounted for a major share in the global market in 2015. The dominance of this regional market is attributed to the large presence of pharmaceutical companies which require premium quality of APIs. However, in the coming years, Asia Pacific is fast emerging as the major hub for API sourcing driven by cost reduction in manufacturing.
Based on therapeutic areas, the cardiovascular disorders segment dominates the market and is projected to expand at a CAGR of 6.63% from 2015 to 2023. The growing prevalence of various cardiac conditions with complicated etiology is expected to boost the active pharmaceutical ingredient market through the forecast period. A number of blockbuster drugs going off-patents is further expected to stimulate the demand for APIs.
Growing Prevalence of Chronic Conditions to Fuel Market
The active pharmaceutical ingredient market is majorly driven by the growing prevalence of a variety of chronic conditions such as cancer, cardiovascular disorders, metabolic disorders, and neurological disorders. Increasing incidence of these diseases has propelled the demand for therapeutics and novel therapies. This has spurred research in drug formulation for more efficacious treatments. In addition, the rapidly growing geriatric population, especially in developed regions of North America and Europe, is expected to stimulate the demand for APIs in making therapies for various ailments.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Active Pharmaceutical Ingredient Market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690
Improving access to quality healthcare in developing regions such as Asia Pacific has propelled the demand for APIs in these regions. In addition, investment by API manufacturers in Asia to adhere to the regulatory compliance requirements, coupled with the tightening regulations by the U.S. FDA on the efficacy of APIs, is expected to boost the global market. However, the growing popularity of generic drugs in developing and resource-poor nations is expected to affect the profit margins of API manufacturers. Nevertheless, various regulatory agencies are working actively to address these concerns, which is expected to unlock exciting opportunities for market players. Substantial spending by various pharmaceutical companies to bolster capacity of API production are also likely to create new opportunities in the market.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Active Pharmaceutical Ingredients (API) Market (Manufacturing Process – Captive Manufacturing and Contract Manufacturing; API Type – Synthetic Chemical API and Biological API; Drug Type – Branded Prescription Drugs, Generic Prescription Drugs, and OTC Prescription Drugs; Therapeutic Area – Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncology, Musculoskeletal Disorders, and NSAIDs) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”